Medpace Holdings Inc

MEDP

NASDAQ. Currency in USD

201.14 -4.86 ( -2.36% )

Real time prices: December 19

Market Cap.
6.26B
Beta (5Y monthly)
1.45
Price/Earnings
32.19
EPS (TTM)
6.52
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
269,162
1y Target Est.
218.33
Day's Range
200.31
-
205.15
52 Week's Range
126.94
-
235.72

Historical Summary

Performance
EPS growth
Share Buybacks

About Medpace Holdings Inc

Sector
Healthcare
Industry
Diagnostics & Research
Website
https://www.medpace.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
35.94M
Employees
5000
Address
5375 Medpace Way, Cincinnati, OH, United States, 45227
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Latest news

Ensign Group (ENSG) Unveils Dividend Hike to Reward Shareholders
Ensign Group (ENSG) Unveils Dividend Hike to Reward Shareholders

Ensign Group's (ENSG) latest dividend hike reflects strong financial standing and intensified focus in the...
By Zacks Investment Research - 5 weeks ago

Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny
Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny

Medpace, HealthEquity and Progyny have been highlighted in this Industry Outlook article.
By Zacks Investment Research - 6 weeks ago

HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery
HCA Healthcare's (HCA) ESR Program Aids Post-Surgery Recovery

HCA Healthcare's (HCA) ESR program remains on track to attract more patients to choose HCA's...
By Zacks Investment Research - 6 weeks ago

3 Medical Services Stocks to Buy Amid Industry Challenges
3 Medical Services Stocks to Buy Amid Industry Challenges

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and...
By Zacks Investment Research - 6 weeks ago

Here's Why Investors Should Retain LabCorp (LH) Stock for Now
Here's Why Investors Should Retain LabCorp (LH) Stock for Now

Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.
By Zacks Investment Research - 7 weeks ago

HealthEquity (HQY) Stock Falls 1.6% Despite Q3 Earnings Beat
HealthEquity (HQY) Stock Falls 1.6% Despite Q3 Earnings Beat

HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust performances in all its segments...
By Zacks Investment Research - 7 weeks ago

Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access
Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access

Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services...
By Zacks Investment Research - 7 weeks ago

Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay
Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay

Quest Diagnostics' (DGX) legacy base business is growing amid softer utilization trends.
By Zacks Investment Research - 7 weeks ago